Chairman, Division of Gastroenterology and Hepatology, Antwerp University Hospital
Global Engage is pleased to announce the 5th Global NASH Congress, which will be taking place on the 26th and 27th of May 2022 in London.
Endorsed by the:
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
However, promising developments in research will hopefully bolster drug development and other methods
of treatment. Examples of such developments include improved in vivo liver models, non-invasive diagnostic biomarkers and a better understanding of the disease’s mechanisms. This year’s congress will focus on these exciting advancements, as well as on the challenges of preclinical and clinical research in NASH. There will also be sessions covering regulation and business development, as well as a showcase of the most promising therapeutics in development.
Attracting experts working in all areas of nonalcoholic steatohepatitis, the conference will examine the latest research and development in pathogenesis, diagnosis and treatment of the disease. Featuring small group roundtable discussions and ample networking time, the event provides an excellent opportunity to meet and collaborate with senior representatives from industry, hospitals and universities. During the two-day conference, there will be more than 30 expert-led presentations, interactive roundtable discussions exploring key issues, and a dynamic exhibition room filled with technology providers showcasing their technologies.
“I really enjoyed the scientific content of the conference with news from providers and Pharma organisations.” Delegate Pharma Company
“There was a good variety of speakers & content with ample networking opportunities” NHS Delegate
“A very good spread of content with topics that were applicable to a wide audience.”Academic delegate
“Well organised, varied content covering the main aspects of NASH and drug development.” Speaker
“I appreciated the broad spectrum of areas within NASH from clinical trials and biomarker to scientific new projects. The conference provided a nice overview of the field as of today.” Sponsor
Professor in Pathology, Chair, Pathology Department, Beaujon Hospital, Clichy, Inserm
This programme creates a collaborative environment in which you can create enduring relationships across the full range of disciplines engaged in NASH research & drug discovery and development.
Updated 1 May 2022
Masks & hand sanitiser will be available at the registration desk.
The meeting is at the end of May. It will be conducted in accordance with the guidance issued at that time from the Department of Health.
At a minimum, it is a condition of entry to the meeting that you have had at least two vaccinations against Covid-19 or that you have had a negative antigen test result taken on 24th or 25th May 2022.
We will require you to complete a declaration confirming your vaccination or test status.